This drug entry is astuband has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Edodekin alfa
- DrugBank Accession Number
- DB15631
- Background
-
Edodekin alfa is under investigation in clinical trial NCT01468896 (Cetuximab and Recombinant Interleukin-12 in Treating Patients With Squamous Cell Carcinoma of the Head and Neck That Is Recurrent, Metastatic, or Cannot Be Removed by Surgery).
- Type
- Biotech
- Groups
- Investigational
- Biologic Classification
-
Protein Based Therapies
Interleukin-based产品 - Protein Chemical Formula
- Not Available
- Protein Average Weight
- Not Available
- Sequences
- Not Available
- Synonyms
-
- Edodekin alfa
- Human il-12 (recombinant)
- Interleukin 12 (human)
- Interleukin-12, human
- Recombinant Human Interleukin-12
- Recombinant interleukin-12
- External IDs
-
- Ro 24-7472
- RO 24-7472/000
- RO-24-7472
- RO-24-7472/000
- RO-247472000
Pharmacology
- Indication
-
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning models
with evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets. - Contraindications & Blackbox Warnings
-
Avoid life-threatening adverse drug eventsImprove clinical decision support with information oncontraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events & improve clinical decision support. - Pharmacodynamics
-
Not Available
- Mechanism of action
- Not Available
- Absorption
-
Not Available
- Volume of distribution
-
Not Available
- Protein binding
-
Not Available
- Metabolism
- Not Available
- Route of elimination
-
Not Available
- Half-life
-
Not Available
- Clearance
-
Not Available
- Adverse Effects
-
Improve decision support & research outcomesWith structured adverse effects data, including:blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Improve decision support & research outcomes with our structured adverse effects data. - Toxicity
-
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRsBrowse all" title="" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
- Not Available
Interactions
- Drug InteractionsLearn More" title="" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
-
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAmbroxol The risk or severity of methemoglobinemia can be increased when Edodekin alfa is combined with Ambroxol. Articaine The risk or severity of methemoglobinemia can be increased when Edodekin alfa is combined with Articaine. Benzocaine The risk or severity of methemoglobinemia can be increased when Edodekin alfa is combined with Benzocaine. Benzyl alcohol The risk or severity of methemoglobinemia can be increased when Edodekin alfa is combined with Benzyl alcohol. Bupivacaine The risk or severity of methemoglobinemia can be increased when Edodekin alfa is combined with Bupivacaine. Butacaine The risk or severity of methemoglobinemia can be increased when Edodekin alfa is combined with Butacaine. Butamben The risk or severity of methemoglobinemia can be increased when Edodekin alfa is combined with Butamben. Capsaicin The risk or severity of methemoglobinemia can be increased when Edodekin alfa is combined with Capsaicin. Chloroprocaine The risk or severity of methemoglobinemia can be increased when Edodekin alfa is combined with Chloroprocaine. Cinchocaine The risk or severity of methemoglobinemia can be increased when Edodekin alfa is combined with Cinchocaine. 
Identify potential medication risksEasily compare up to 40 drugs with our drug interaction checker.Get severity rating, description, and management advice.Learn more - Food Interactions
- Not Available
Categories
- Drug Categories
-
- Adjuvants, Immunologic
- Amino Acids, Peptides, and Proteins
- Angiogenesis Inhibitors
- Angiogenesis Modulating Agents
- Antineoplastic Agents
- Biological Factors
- Cytokines
- Growth Inhibitors
- Growth Substances
- Immunologic Factors
- 细胞间信号肽和蛋白质
- Interleukin-12, antagonists & inhibitors
- Interleukins
- Peptides
- Proteins
- Chemical TaxonomyProvided byClassyfire
-
- Description
- Not Available
- Kingdom
- Organic Compounds
- Super Class
- Organic Acids
- Class
- Carboxylic Acids and Derivatives
- Sub Class
- Amino Acids, Peptides, and Analogues
- Direct Parent
- Peptides
- Alternative Parents
- Not Available
- Substituents
- Not Available
- Molecular Framework
- Not Available
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 31Z82G8ME1
- CAS number
- 187348-17-0
References
- General References
- Not Available
- External Links
Clinical Trials
- Clinical TrialsLearn More" title="" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
Pharmacoeconomics
- Manufacturers
-
Not Available
- Packagers
-
Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
Drug created at March 07, 2020 20:05 / Updated at January 14, 2023 19:02